- Home
- AEMD vs RDHL Comparison
AEMD vs RDHL Comparison
Compare AEMD & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEMD | RDHL |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | Israel |
| Employees | 9 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 3.7M |
| IPO Year | 2008 | 2012 |
Fundamental Metrics
Financial Performance| Metric | AEMD | RDHL |
|---|---|---|
| Price | $5.47 | $0.43 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $13.25 | N/A |
| AVG Volume (30 Days) | 54.1K | ★ 869.8K |
| Earning Date | 11-16-2026 | 09-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17,592.31 |
| Revenue Next Year | N/A | $25.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.38 |
| 52 Week High | $25.66 | $1.60 |
Technical Indicators
Market Signals| Indicator | AEMD | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 43.31 |
| Support Level | $4.86 | $0.38 |
| Resistance Level | $6.69 | $0.71 |
| Average True Range (ATR) | 0.39 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 45.61 | 35.77 |
Price Performance
Historical ComparisonAbout AEMD Aethlon Medical Inc.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
About RDHL Redhill Biopharma Ltd.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.